Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Minutia
Oakland, California, United Statesminutia.co ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Minutia has demonstrated a minimally invasive outpatient transplant procedure using insulin-producing cells with nanosensors in a PI-led Phase 1/2 clinical trial at UCSF. Early results show promising safety and proof-of-concept data, with the goal of providing a functional cure for T1D and enabling real-time monitoring of transplanted cells to improve outcomes.[2][4]
- Therapeutic areas
- Endocrinology
- Modalities
- Stem cell-derived insulin-producing cellsNanosensor-enabled cell therapiesCell and gene therapy technologies[1][2][4]
- Industry
- Biotech
02
Partnerships
Oregon Health & Sciences University (OHSU)[1]
Beyond the preview
Go deeper on Minutia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Minutia.